ContraVir's James Sapirstein Interviewed On Future Of Combination Therapy In HBV
Executive Summary
At BioPharm America 2016, ContraVir CEO James Sapirstein explains how CMX157, a lipid formulation of tenofovir (Gilead's Viread for HIV and hepatitis B), could become a backbone agent for advances in combination therapy in hep B.
You may also be interested in...
ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy
Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.
ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer
ContraVir Pharmaceuticals Inc. is merging with competitor early stage hepatitis B drug developer Ciclofilin Pharmaceuticals to strengthen its pipeline offering in antivirals.
Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo
With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval plus a move into first-line therapy.